Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are already scheduled to receive Y90 radioembolization therapy using SIR-Spheres or TheraSpheres (a type of internal radiation treatment)
- People who are able to stay at the hospital for extra PET/CT scans (a type of medical imaging) after their treatment
- People who are able to have additional blood samples taken before, during, and after their radioembolization procedure
Who may not be able to join:
- People who are not suitable candidates for Y90 radioembolization therapy
- People who are unable to tolerate extra imaging procedures after treatment
- People who are unable to have the additional blood draws required for this study
- People whose schedule does not allow them to remain at the hospital long enough for the extra PET/CT imaging sessions
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dustin Osborne, PhD, University of Tennessee
Phone: 8653058264
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Feasibility of Active Dose Delivery Monitoring; Measurement and Assessment of Free, Circulating Yttrium 90; Therapy Monitoring Using Whole-Body Post-therapy PET/CT Imaging
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.